www.bioworld.com/articles/495145

FAVORABLE COMMENTS SPUR STOCKS

Sep. 20, 1991

Positive comments by analysts helped several biotechnologystocks enjoy strong gains on Thursday.

Buoyed by comments this week by Montgomery Securitiesanalyst Brandon Fradd, Genetic Therapy Inc. (NASDAQ:GTII)closed up $2.75 at $12.50; Glycomed Inc. (NASDAQ:GLYC) rose$3.25 to $14; and ImmunoGen Inc. (NASDAQ:IMGN) closed up $2at $20.25, after gaining $2 on Wednesday.

Regeneron Pharmaceuticals Inc. stock (NASDAQ:REGN) rose$3.38 to $16 after a "buy" recommendation from Larry Bloom ofSoundView Financial Group. Earlier this month, Kevin Wilson ofS.G. Warburg Securities also issued a buy on the stock, whichcompleted an initial public offering in April at $22 per share.

Several agricultural biotech stocks rose, apparently as aresult of public comments by Jim McCamant, editor of theBerkeley, Calif.-based AgBiotech Stock Letter. McCamant,reiterating comments in his September newsletter, saidThursday that agbio stocks are undervalued.

Crop Genetics International Corp. (NASDAQ:CROP) was up $1.38to $4.63; Mycogen Corp. stock (NASDAQ:MYCO) was up 13 centsto $15.75 after gaining $1.88 on Wednesday; and Calgene Inc.stock (NASDAQ:CGNE) rose $1.25 to $9.